MIT-BIHArrhythmia Database
Discuss licensing 01 Evidence overview
Evidence you can see in the signal.
A public technical view of patient-separated evaluation, benchmark comparison, and PVC sensitivity.
02 Research signalA patient-separated view
A patient-separated view
of PVC sensitivity.
Training cohort
92.7%PVC sensitivity
Separated test cohort
Zeroper-patient setup
77.7% VEB sensitivityDe Chazal et al., 2004
Research validationReplication recommended
Inventor-reported under an evaluation described as AAMI EC57-aligned. Independent replication remains recommended.
03 Signal comparisonSee the event—not
See the event—not
only the percentage.
Illustrative waveform visualization showing how a PVC event can be surfaced inside a longer ECG sequence.
04 Evaluation disciplineWhat the public evidence
What the public evidence
does—and does not—establish.
Recognized test material
MIT-BIH is a widely used public dataset for evaluating arrhythmia detection and heartbeat classification systems.
92.7%
77.7%
77.7%Comparison discipline
The two figures should not be treated as fully equivalent until protocols, beat groupings, and scoring are independently audited.
Clinical boundary
The technology is investigational and is not FDA cleared. Future device use would require appropriate validation and a regulatory pathway.
05 ClosingReview the evidence
Review the evidence
behind the classification.
Let’s connect to discuss how Arrhyva can integrate into your platform and workflows.